A combination of chemotherapy and chimeric antigen receptor (CAR) T cells designed to target the protein HER2 was found to be safe and showed clinical responses in pediatric and adult patients with advanced HER2-positive sarcoma, according to results from a phase I clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3.
from EurekAlert! - Breaking News https://ift.tt/2JQSJ5O
via IFTTT
Monday, April 1, 2019
HER2-targeted CAR T-cell therapy shows promising antitumor activity in patients with sarcoma
About Admin -
Author Description here.. Nulla sagittis convallis. Curabitur consequat. Quisque metus enim, venenatis fermentum, mollis in, porta et, nibh. Duis vulputate elit in elit. Mauris dictum libero id justo.